Come up with a name for your new list and we'll add to it:
OrPro Therapeutics raised a round of funding on July 31, 2012. Investors include
National Heart Lung and Blood Institute.
OrPro Therapeutics is a pre-clinical stage biopharmaceutical company developing a class of safe, well-tolerated and effective inhaled non-systemic drugs based on the thioredoxin active site for the tr…